Resmed Inc. Stock
Price
Target price
€176.20
€176.20
1.210%
2.1
1.210%
€198.11
02.07.24 / Tradegate
WKN: 895878 / Symbol: RMD / Name: ResMed / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Resmed Inc. Stock
There is an upward development for Resmed Inc. compared to yesterday, with an increase of €2.10 (1.210%).
With 19 Buy predictions and not the single Sell prediction the community is currently very high on Resmed Inc..
With a target price of 198 € there is a slightly positive potential of 12.37% for Resmed Inc. compared to the current price of 176.2 €.
Pros and Cons of Resmed Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Cons
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Resmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Resmed Inc. | 1.210% | 2.681% | -7.361% | -12.032% | 12.408% | -16.532% | 62.068% |
| QuidelOrtho Corp. | -1.350% | -5.195% | -28.431% | -60.805% | -56.945% | -72.348% | - |
| Boston Scientific | 0.000% | -1.379% | 2.143% | 44.299% | 38.997% | 93.087% | 88.505% |
| Waters Corp. | -1.410% | -1.158% | -6.796% | 7.602% | -12.351% | -11.767% | 42.067% |
Comments
ResMed Inc. (NYSE: RMD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $236.00 price target on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed Inc. (NYSE: RMD) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $205.00 to $200.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed Inc. (NYSE: RMD) had its price target raised by analysts at KeyCorp from $227.00 to $238.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
News
How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You?
ResMed has had the market on sleep apnea cornered for a while, but new weight loss drugs might be creeping in. In this podcast, we look at what could change based on recent studies and some other
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is
Why ResMed Stock Is Soaring Today
Shares of ResMed (NYSE: RMD) had soared 16.2% higher as of 11:50 a.m. ET on Friday. The big jump came after the healthcare technology company reported results on Thursday evening for its fiscal 2024